Table 2 The correlation between MNDA expression and important clinicopathological parameters in DLBCL
Parameter | Total cases (N = 213) | MNDA expression(%) | p-value | |
|---|---|---|---|---|
Immunotype | <0.001 | |||
Non-GCB | 113 | 45(39.8) | ||
GCB | 86 | 14(16.3) | ||
ND | 14 | |||
Gender | 0.057 | |||
Female | 116 | 28(24.1) | ||
Male | 97 | 35(36.1) | ||
Location | 0.179 | |||
Nodal | 36 | 14(38.9) | ||
Extra-nodal | 177 | 49(27.7) | ||
EBER | 0.290 | |||
Positive | 17 | 4(23.5) | ||
Negative | 123 | 45(36.6) | ||
ND | 73 | |||
BCL2 | 0.004 | |||
Positive | 122 | 46(37.7) | ||
Negative | 85 | 16(18.8) | ||
ND | 6 | |||
MYC | 0.094 | |||
Positive | 94 | 36(38.3) | ||
Negative | 73 | 19(26.0) | ||
ND | 46 | |||
BCL2/MYC DE | 0.001 | |||
Positive | 56 | 28(50.0) | ||
Negative | 109 | 27(24.8) | ||
ND | 48 | |||
CD5 | 0.036 | |||
Positive | 17 | 9(52.9) | ||
Negative | 176 | 50(28.4) | ||
ND | 20 | |||
CD30 | 0.568 | |||
Positive | 16 | 5(31.2) | ||
Negative | 72 | 28(38.9) | ||
ND | 125 | |||